Omnicell (OMCL) Cash from Operations Growth (3y) (2013 - 2026)
Powered by 
Analysis
Omnicell (OMCL) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | 27.41% |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | 16.81% |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | 27.02% |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | 22.38% |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | 30.85% |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | 168.71% |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | 16.21% |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | 12.26% |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn | 24.18% |
| 10 | Omnicell | 1.57 Bn | 1.28 Bn | 152.94 Mn | -2.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.14% |
| Mar 31, 2026 | 62.21% |
| Dec 31, 2025 | -28.24% |
| Sep 30, 2025 | 10.11% |
| Jun 30, 2025 | 86.40% |
| Mar 31, 2025 | 53.55% |
| Dec 31, 2024 | -1.89% |
| Sep 30, 2024 | -19.11% |
| Jun 30, 2024 | -6.48% |
| Mar 31, 2024 | -4.53% |
| Dec 31, 2023 | -20.50% |
| Sep 30, 2023 | 15.83% |
| Jun 30, 2023 | 15.35% |
| Mar 31, 2023 | -20.31% |
| Dec 31, 2022 | 33.13% |
| Sep 30, 2022 | -27.87% |
| Jun 30, 2022 | -32.96% |
| Mar 31, 2022 | -37.57% |
| Dec 31, 2021 | 7.91% |
| Sep 30, 2021 | 39.64% |